However, the long-term effects of myocarditis in children associated with COVID-19 vaccination are unknown
FRIDAY, Sept. 3, 2021 (HealthDay News) — Myocarditis has been reported in children following receipt of the Pfizer-BioNTech COVID-19 vaccine, according to a case series published online Aug. 10 in JAMA Cardiology.
Audrey Dionne, M.D., from Boston Children’s Hospital, and colleagues reviewed results of comprehensive cardiac imaging in 15 children (14 males; median age, 15 years) hospitalized with myocarditis within 30 days of receiving the Pfizer-BioNTech COVID-19 vaccine.
The researchers reported that symptoms started one to six days after receipt of the vaccine and included chest pain in all patients, fever in 10 patients, myalgia in eight patients, and headache in six patients. All patients at admission had elevated troponin levels (median, 0.25 ng/mL), which peaked 0.1 to 2.3 days after admission. Echocardiographic examination revealed decreased left ventricular ejection fraction in three patients and abnormal global longitudinal or circumferential strain in five patients. No pericardial effusion was seen. Findings of cardiac magnetic resonance imaging were consistent with myocarditis in 13 patients, including late gadolinium enhancement in 12 patients. Median hospital length of stay was two days, symptoms resolved in 73 percent of patients at follow-up one to 13 days after hospital discharge.
“COVID-19 vaccine-associated myocarditis may have a benign short-term course in children; however, the long-term risks remain unknown,” the authors write.
Iron Supplementation Likely to Reduce Iron-Deficiency Anemia in Children
EHR-Enabled QI Intervention Improves Chlamydia, Gonorrhea Screening in Teens
Serum Carotenoid Levels Have Positive Impact on COPD Health Status
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
Rates of Drug Use-Associated Infective Endocarditis Declined From 2020 to 2022
Nonpharmacologic Therapy Cuts Opioid Use Disorder Risk With Low Back Pain
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Withdrawal From Medetomidine Increasingly Seen in ICUs